Conversely, research utilizing a spontaneous breast cancer model characterized by high VEGF sensitivity revealed that treatment with FG-4497, a HIF-PHI drug of the same class as Roxadustat, did not enhance tumorigenesis or progression, even though VEGF levels were elevated (Seeley et al., 2017). Here, VEGFA is linked to breast carcinoma.